Speakers

Expand/Collapse

Agnieszka Denslow
Associate Director
Pharmacology / Toxicology, Oncorus

Day Two

Thursday, July 14, 2022

8:30 am | Modelling Small Cell Lung Cancer in Preclinical Development of Synthetic Oncolytic Virus

Andrew Puca
Director, Corporate & Commercial Development
The Jackson Laboratory

Day One

Wednesday, July 13, 2022

9:30 am | Leveraging the Power of Novel Humanized Models to Support Preclinical Oncology Studies in the Context of Changing FDA Pre-IND Requirements

Anita Seshire
Head Of Laboratory in Exploratory Cancer Research, Translational Innovation Platform Oncology- Immunooncology
EMD Serono

Day One

Wednesday, July 13, 2022

4:20 pm | Developing Clinically Translatable Models that Accurately Represent Patient Metastasis

Beatrice Wang
Associate Director
IGM Biosciences

Day One

Wednesday, July 13, 2022

8:00 am | Combination of a Multimeric Anti-DR5 IgM Antibody with Targeted Agents Induces Synergistic Tumor Cytotoxicity in Vitro & in Vivo

David Draper
Associate Director, Scientific Development
Labcorp

Day One

Wednesday, July 13, 2022

3:15 pm | Session Reserved for Labcorp

Douglas Palmer
Executive Director of Immuno-Oncology Translational Medicine
AstraZeneca

Translation Track - Day 1 am

12:45 pm | Roundtable Discussion: Right Tumor, Right Model, Wrong Drug

Douglas Powell
Director, Scientific Engagement
Crown Bioscience

Day One

Wednesday, July 13, 2022

8:30 am | Leveraging PDX-derived Organoid (PDXO) Models for Combination Targeted Oncology

Eric Ibsen
Chief Executive Officer
Studylog

Esmaiel Jabarri
Professor
University of South Carolina

Day Two

Thursday, July 14, 2022

2:45 pm | 3D Screening Model for Combination Drugs Against Tumor Differentiated & Undifferentiated Cells

Frank Sun
Senior Principal Scientist, Oncology Pharmacology
Sanofi

Preclinical Track - Day 1 am

11:45 am | Humanized Mouse Model as a Translational Tool for Immunotherapy in Oncology

Gareth Griffiths
CSO
Imagen Therapeutics

Day One

Wednesday, July 13, 2022

10:00 am | Patient-Derived Cell (PDC) Models as a Tool to Assess Cancer Therapeutic Efficacy Across the Drug Development Life Cycle

Javier Pineda
Bioinformatics Lead
Scientist.com

Day Two

Thursday, July 14, 2022

12:00 pm | The Disease Model Finder: An AI-Powered Platform to Enhance Disease Model Sourcing

Jean Viallet, PhD.
CEO/CSO
Inovotion

Day Two

Thursday, July 14, 2022

10:45 am | Combination Approach: Using Chicken Egg In vivo assay for High-Value Identification of Oncology and Immuno-Oncology drugs Candidates

Jenna Frame
PhD, Sr. Manager, Scientific Communications & Marketing
Biocytogen

Day One

Wednesday, July 13, 2022

4:50 pm | Preclinical Evaluation of Novel Combination Therapies Using Multigenic Humanized Models

Jessica Haverkamp
Associate Director Macrophage Biology
BlueRock Therapeutics

Day One

Wednesday, July 13, 2022

5:20 pm | Chair’s Closing Remarks & End of Conference Day One

7:50 am | Chair’s Opening Remarks

Preclinical Track - Day 1 am

11:15 am | Fireside chat: Utilizing RNA-Seq for Better Pre-Clinical Predictions & Patient Identification

Jingjing Jiang
Senior Director, Translational Research
Revolution Medicines

Translation Track - Day 1 am

11:45 am | Combination Therapy to Outsmart RASAddicted Cancer - Informing Clinical Strategy with Preclinical Modeling

Johanna K. Kaufmann
EVP Oncology
Codagenix

Johanna Lahdenranta
Director In Vivo Pharmacology
Bicycle Therapeutics

Translation Track - Day 1 am

12:15 pm | Exploring Tumor Localized CD137 Agonism with Bicycle Tumor-Targeted Immune Cell Agonists (Bicycle TICAs®)

Juan Arriaga
Assistant Professor – Department of Oncological Sciences & Urology
Icahn School of Medicine at Mount Sinai

Day One

Wednesday, July 13, 2022

2:45 pm | Modeling Bone Metastasis of Prostate Cancer

Day Two

Thursday, July 14, 2022

3:45 pm | Panel Discussion - What Are the Advantages of 3D Models

Julie Gerardi
VP, Viological Modeling & Functional Genomics Business Development
Tempus

Day Two

Thursday, July 14, 2022

9:00 am | Applying Real-World Data & Tumor Modeling to Discovery & Translational Research

Jun Zhang
MD, PhD, Associate Professor
University of Kansas Medical Center, Medical Oncology

Kader Thiam
SVP Discovery - Preclinical Models & Services
Genoway

Day One

Wednesday, July 13, 2022

2:15 pm | Precise and translational preclinical models for assessment of immune-targeting agents

Katie Grausam
Postdoctoral Scientist
Cedars Sinai

Day Two

Thursday, July 14, 2022

11:15 am | Weighing up Pros & Cons of Quick & Dirty Models Versus Slower Growing Models

3:45 pm | Panel Discussion - What Are the Advantages of 3D Models

Khalid Shah
Vice Chairman at BWH
Harvard Medical School

Day One

Wednesday, July 13, 2022

9:00 am | Translatability at a Glance: Combined Gene Edited & Engineered Cellular Therapies for Solid Tumors

Kimberly Aardalen
Scientific Technical Leader
Novartis Institutes for Biomedical Research

Ludovic Bigot
Project Manager
Gustav Rousey

Day Two

Thursday, July 14, 2022

2:15 pm | MATCH-R: A Preclinical Platform of Resistant Models to Innovative Therapies • Highlighting the development of a panel

Marc Pelletier
Senior Principal Scientist
Novartis

Preclinical Track - Day 1 am

11:15 am | Fireside chat: Utilizing RNA-Seq for Better Pre-Clinical Predictions & Patient Identification

Marc Zuckermann
Group Leader Preclinical Modeling
German Cancer Research Center (DKFZ)

Translation Track - Day 1 am

11:15 am | Targeting c-MET in Combination with Radiation is Effective in MET-Fusion Driven High- Grade Glioma

Marco Campisi
Postdoctoral Research Fellow
Dana-Farber Cancer Institute

Day Two

Thursday, July 14, 2022

3:45 pm | Panel Discussion - What Are the Advantages of 3D Models

1:15 pm | Retaining the Tumor Immune Microenvironment Heterogeneity & Vascular Cross-talks in Ex-Vivo Microphysiological Models

Mark Moore PhD
CEO
GemPharmatech

Day One

Wednesday, July 13, 2022

3:50 pm | Accelerating Antibody Research Using Humanized Mouse Models

Matthew Hebb
Neurosurgeon Scientist
University of Western Ontario

Day Two

Thursday, July 14, 2022

11:45 am | Orthotopic & Metastatic Xenograft Studies in the SRG Rat

Monika Buczek
PhD, Director of Business Development
Business Development

Day Two

Thursday, July 14, 2022

10:00 am | Translating Preclinical Combinatorial Therapy Approaches in In Vitro & In Vivo Models of Human Glioblastoma Multiforme

Natalia Blanco
Associate Director, Immuno-Oncology
Morphic Therapeutic

Preclinical Track - Day 1 am

12:30 pm | Treatment Modalities to Improve Response in Tumors Refractory to Standard Immunotherapy Approaches

Scott Boiko
Associate Director Translational Science
Forma Therapeutics

Day Two

Thursday, July 14, 2022

9:15 am | Roundtable: Outlining Model Validation & Establishing the Need for Standardization

4:45 pm | Chair’s Closing Remarks & End Of Summit

8:20 am | Chair’s Opening Remarks

Senior Representative

Hera BioLabs

Shiva Kazerounian
Associate Director of in Vivo Pharmacology
Berg Health

Soner Altiok
CSO
Nilogen Oncosystems

Tessa DesRochers
Chief Scientific Officer
Kiyatec Inc

Preclinical Track - Day 1 am

12:15 pm | De-Risking Drug Development by Incorporating Clinically Correlated Ex Vivo Models

Thomas Schürpf
Senior Director, Tumor Biology
Parthenon Therapeutics

Day Two

Thursday, July 14, 2022

4:15 pm | Breaking Down Barriers In Immune-Excluded Tumor Biology

Tomasz Owczarek
Senior Staff Scientist
Regeneron

Day Two

Thursday, July 14, 2022

1:45 pm | Model Selection for Tumor Heterogeneity & TME

William Coward
Business Development Manager
Nilogen Oncosystems